Replies to post #14884 on RespireRx Pharmaceuticals Inc (RSPI)

[Aiming4]

enemem - per your quote, do you think there is a consensus on the board about COR right now?

My impression is that opinions are varied right now about Cortex's future if the RD trial is successful, and the only consensus is that it will be very bleak if there are problems with RD.

[neuroinv]

I agree that the general view of the RD indication potential expressed on this thread is an underestimate. But the question yet-to-be-answered is: Will a potential partner offer an upfront that reflects chronic use potential before there is any chronic use data at all? I expect that the most likely initial offers will include a second major (maybe bigger) milestone payment upon successful completion of a chronic use Phase IIa, that way the BP isn't taking the risk in advamce. However, as you accurately note, there are a number of pain companies who could bid against each other for this technology, and that raises the likelihood that one of them would 'break from the pack' and offer a larger upfront payment, instead of relying upon a contingent milestone.

NeuroInvestment